Annual Secretarial Compliance Report for the year ended 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Godavari Drugs Ltd has filed its Annual Secretarial Compliance Report for FY 2025-26, reviewed by VSS & Associates, Company Secretaries. The report confirms the company largely complied with SEBI regulations during the review period. However, two specific deviations were noted: (1) Late submissions of regulatory filings under Regulations 13(3), 19(1)/19(2), 17(1A), 23(9), and 34 of SEBI LODR — these were unintentional oversights and the company has paid all outstanding fines of Rs 1,84,000 via NEFT; (2) Several mandatory disclosures under Regulation 46 could not be located on the company's website, for which BSE sent a compliance email on April 23, 2026. The company stated it is taking steps to update its website. All other compliance areas including Secretarial Standards, Insider Trading norms, Related Party Transactions, and Performance Evaluation were found satisfactory.
Minor regulatory concern — past late filing fines have been paid, but website disclosure gaps need to be addressed. This is a routine compliance filing with no direct impact on stock price, though persistent non-compliance could attract regulatory scrutiny.